Sweden approves generic copy of GSK's top lung drug
LONDON Jan 14 (Reuters) - Sweden has followed Denmark and Germany in approving the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair.
Britain's Vectura said on Tuesday its partner Sandoz, the generics division of Switzerland's Novartis , had received Swedish authorisation for its generic version of the drug, known as AirFluSal Forspiro.
The initial Danish green light was given to the product in December.
- Maine nurse fights Ebola quarantine, says will not be bullied |
- Dollar surges as Fed ends QE on hawkish note
- SoftBank's humanoid robot lands job as Nescafe salesman
- Clashes erupt as Israeli police kill Palestinian suspected of shooting Jewish far-rightist
- Ukraine gas supplies in doubt as Russia seeks EU payment deal